Tryptophan dendrimers, originally designed to inhibit HIV, are also potent inhibitors of enterovirus A71 replication.
Answers are grounded in this paper and cite their sources.
May support preclinical development against enterovirus A71; leaves open clinical translation.
Tryptophan dendrimers that inhibit HIV replication by binding to the HIV envelope glycoproteins gp120 and gp41 have unexpectedly also proven to be potent, specific, and selective inhibitors of the replication of the unrelated enterovirus A71. Dendrimer 12, a consensus compound that was synthesized on the basis of the structure-activity relationship analysis of this series, is 3-fold more potent against the BrCr lab strain and, surprisingly, inhibits a large panel of clinical isolates in the low-nanomolar/high-picomolar range.
No takes yet. Share an insight, caveat, or question.
Rivero‐Buceta et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: